Skip to main content

Market Overview

Moderna Posts Data From Early mRNA Flu Vaccine Study, Pivotal Trial On Its Way

Share:
Moderna Posts Data From Early mRNA Flu Vaccine Study, Pivotal Trial On Its Way
  • Moderna Inc (NASDAQ: MRNA) says that it's on its way to having two mRNA vaccines against different seasonal flu viruses.
  • The Company released the first early data from Phase 1 study of mRNA-1010, announcing that all doses of the shot significantly boosted antibodies in younger and older adults without "significant safety findings." 
  • Moderna said the 50 microgram dose increased antibodies against the two Influenza A strains by eight-fold and ten-fold, respectively, and against the other two influenza strains by three-fold and two-fold.
  • For now, the investors appear primarily bearish, as they will compare Moderna's data with early results from the ongoing Phase 1 trial from BioNTech SE (NASDAQ: BNTX) and Sanofi SA's (NASDAQ: SNYTranslate Bio Inc in the coming months. 
  • Related Link: Pfizer Joins Influenza Vaccine Race, Kick Starts Early-Stage Trial.
  • A 500-person Phase 2 dose-confirming study is already enrolled, the Company said, and preparations for a large pivotal trial are underway.
  • The Phase 2 study of mRNA-1010 was initiated in November to confirm dose across three dose levels, including a lower 25 µg dose level and 50 µg & 100 µg with approximately 150 participants per arm. An interim analysis is expected in early 2022.
  • Price Action: MRNA shares are down 9.33 at $246.80 during the market session on the last check Friday.
 

Related Articles (MRNA + BNTX)

View Comments and Join the Discussion!

Posted-In: Briefs influenzaBiotech News Health Care Movers Trading Ideas General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com